NO20054095L - Pyridyloksymetyl og benzioksazolazabicyklisk derivater - Google Patents

Pyridyloksymetyl og benzioksazolazabicyklisk derivater

Info

Publication number: NO20054095L
Authority: NO; Norway
Prior art keywords: alkoxy; hydrogen; alkyl; disorders; oxygen
Prior art date: 2003-03-12

Application number

NO20054095A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054095D0 (no

Inventor

Gene Michael Bright

Bishop Wlodecki

Michael Aaron Brodney

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-12

Filing date

2005-09-02

Publication date

2005-09-26

2005-09-02 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2005-09-02 Publication of NO20054095D0 publication Critical patent/NO20054095D0/no

2005-09-26 Publication of NO20054095L publication Critical patent/NO20054095L/no

Links

229910052739 hydrogen Inorganic materials 0.000 abstract 4
239000001257 hydrogen Substances 0.000 abstract 4
125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
150000002431 hydrogen Chemical group 0.000 abstract 2
229910052760 oxygen Inorganic materials 0.000 abstract 2
239000001301 oxygen Substances 0.000 abstract 2
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
208000020401 Depressive disease Diseases 0.000 abstract 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
125000003545 alkoxy group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229910052736 halogen Inorganic materials 0.000 abstract 1
125000005843 halogen group Chemical group 0.000 abstract 1
150000002367 halogens Chemical class 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
201000000980 schizophrenia Diseases 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1
229910052717 sulfur Inorganic materials 0.000 abstract 1
239000011593 sulfur Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Gynecology & Obstetrics (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Dermatology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Epidemiology (AREA)
Pregnancy & Childbirth (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

NO20054095A 2003-03-12 2005-09-02 Pyridyloksymetyl og benzioksazolazabicyklisk derivater NO20054095L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US45392503P	2003-03-12	2003-03-12
PCT/IB2004/000499 WO2004081007A1 (fr)	2003-03-12	2004-02-23	Derives azabicycliques de pyridyloxymethyl et de benzisoxazole

Publications (2)

Publication Number	Publication Date
NO20054095D0 NO20054095D0 (no)	2005-09-02
NO20054095L true NO20054095L (no)	2005-09-26

Family

ID=32990837

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054095A NO20054095L (no)	2003-03-12	2005-09-02	Pyridyloksymetyl og benzioksazolazabicyklisk derivater

Country Status (30)

Country	Link
US (1)	US7345038B2 (fr)
EP (1)	EP1608648B1 (fr)
JP (2)	JP3910627B2 (fr)
KR (2)	KR100767854B1 (fr)
CN (1)	CN100389115C (fr)
AP (1)	AP2005003390A0 (fr)
AR (1)	AR043537A1 (fr)
AU (2)	AU2004220327B2 (fr)
BR (1)	BRPI0408248A (fr)
CA (1)	CA2518740C (fr)
EA (1)	EA009527B1 (fr)
EC (1)	ECSP056011A (fr)
GT (1)	GT200400041A (fr)
HR (1)	HRP20050798A2 (fr)
IL (1)	IL170290A (fr)
MA (1)	MA27747A1 (fr)
MX (1)	MXPA05009660A (fr)
NL (1)	NL1025710C2 (fr)
NO (1)	NO20054095L (fr)
OA (1)	OA13038A (fr)
PA (1)	PA8597501A1 (fr)
PE (1)	PE20041057A1 (fr)
PL (1)	PL378749A1 (fr)
RS (1)	RS20050692A (fr)
TN (1)	TNSN05224A1 (fr)
TW (1)	TW200502234A (fr)
UA (1)	UA78437C2 (fr)
UY (1)	UY28225A1 (fr)
WO (1)	WO2004081007A1 (fr)
ZA (1)	ZA200506373B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6994726B2 (en) *	2004-05-25	2006-02-07	Calcitec, Inc.	Dual function prosthetic bone implant and method for preparing the same
ES2372694T3 (es) *	2003-10-15	2012-01-25	OSI Pharmaceuticals, LLC	Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
WO2005082370A1 (fr) *	2004-01-29	2005-09-09	Pfizer Products Inc.	Combinaisons d'un antipsychotique atypique et de derives azabicycliques d'aminomethylpyridyloxy- methyle/benzisoxazole pour le traitement de troubles du systeme nerveux central
HRP20090495T1 (hr) *	2004-04-02	2009-10-31	Osi Pharmaceuticals	Heterobiciklički inhibitori protein kinaze supstituirani 6,6-bicikličkim prstenom
AR053090A1 (es)	2004-07-20	2007-04-25	Osi Pharm Inc	Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
JP2008512441A (ja) *	2004-09-10	2008-04-24	ファイザー・プロダクツ・インク	ピリジルオキシメチル、及びベンズイソオキサゾール・アザビシクロ誘導体を使用する、認知障害の治療方法
US8575164B2 (en) *	2005-12-19	2013-11-05	OSI Pharmaceuticals, LLC	Combination cancer therapy
JP2011510018A (ja) *	2008-01-18	2011-03-31	オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド	癌治療のためのイミダゾピラジノール誘導体
EP2283020B8 (fr) *	2008-05-19	2012-12-12	OSI Pharmaceuticals, LLC	Imidazopyrazines et imidazotriazines substituées
CN102405214A (zh)	2009-04-20	2012-04-04	Osi药物有限责任公司	C-吡嗪-甲胺的制备
JP2012526138A (ja) *	2009-05-07	2012-10-25	オーエスアイ・ファーマシューティカルズ，エルエルシー	副腎皮質癌を治療するためのｏｓｉ−９０６の使用
US9394290B2 (en) *	2010-10-21	2016-07-19	Universitaet Des Saarlandes Campus Saarbruecken	Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
WO2014078568A1 (fr)	2012-11-14	2014-05-22	The Johns Hopkins University	Méthodes et compositions pour le traitement de la schizophrénie
US9980945B2 (en)	2015-01-13	2018-05-29	Vanderbilt University	Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US9585867B2 (en)	2015-08-06	2017-03-07	Charles Everett Ankner	Cannabinod formulation for the sedation of a human or animal
WO2020183011A1 (fr)	2019-03-14	2020-09-17	Institut Curie	Inhibiteurs de htr1d et leurs utilisations dans le traitement du cancer
WO2023083445A1 (fr)	2021-11-10	2023-05-19	Symrise Ag	Compositions comprenant des agents de refroidissement agonistes de trpm8

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX19222A (es)	1989-01-23	1993-12-01	Pfizer	Agentes ansioliticos bis-aza-biciclicos
US5167034A (en) *	1990-06-18	1992-11-24	International Business Machines Corporation	Data integrity for compaction devices
US5157034A (en)	1991-02-27	1992-10-20	Pfizer Inc.	Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
CA2118936A1 (fr)	1991-09-25	1993-04-01	Gene M. Bright	Derives de substitution en 2 de perhydro-1-h-pyrido[1,2-a]pyrazines, agent neuroleptiques
ATE185565T1 (de)	1992-06-16	1999-10-15	Pfizer	Verfahren und zwischenprodukte zur herstellung von bis-aza-bicyclischen anxiolytica
US5731307A (en)	1994-09-30	1998-03-24	Pfizer, Inc.	Neuroleptic 2,7-disubtituted perhydro-1h-pyrido 1, 2-A!pyrazines
CA2289574C (fr)	1997-05-30	2007-04-24	Neurosearch A/S	Derives de 8-azabicyclo[3.2.1]oct-2-ene et -octane utilises comme ligands cholinergiques de recepteurs nicotiniques de l'ach
PA8469101A1 (es) *	1998-04-09	2000-09-29	Pfizer Prod Inc	Ligandos azabiciclicos de receptores 5ht1
SK2612001A3 (en)	1998-08-26	2001-11-06	Aventis Pharma Ltd	Aza-bicycles which modulate the inhibition of cell adhesion
HK1039326A1 (zh)	1998-09-18	2002-04-19	Abbott Gmbh & Co. Kg	4氨基吡咯并嘧啶作为激酶抑制剂
HK1039325B (en)	1998-09-18	2006-02-24	Abbott Gmbh & Co. Kg	4-aminopyrrolopyrimidines as kinase inhibitors
UA62015C2 (en) *	1998-12-28	2003-12-15	Pfizer Prod Inc	Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
HUP0202248A3 (en)	1999-03-12	2006-06-28	Boehringer Ingelheim Pharma	Compounds useful as anti-inflammatory agents
EP1177792A3 (fr) *	2000-07-27	2002-10-23	Pfizer Products Inc.	Ligands dopamine d4 destines au traitement des troubles associees a la cherche de la nouveaute

2004
- 2004-02-23 AP AP2005003390A patent/AP2005003390A0/xx unknown
- 2004-02-23 KR KR1020057016859A patent/KR100767854B1/ko not_active Expired - Fee Related
- 2004-02-23 JP JP2006506261A patent/JP3910627B2/ja not_active Expired - Fee Related
- 2004-02-23 PL PL378749A patent/PL378749A1/pl not_active Application Discontinuation
- 2004-02-23 CA CA2518740A patent/CA2518740C/fr not_active Expired - Fee Related
- 2004-02-23 EA EA200501148A patent/EA009527B1/ru not_active IP Right Cessation
- 2004-02-23 EP EP04713592A patent/EP1608648B1/fr not_active Expired - Lifetime
- 2004-02-23 CN CNB2004800066516A patent/CN100389115C/zh not_active Expired - Fee Related
- 2004-02-23 WO PCT/IB2004/000499 patent/WO2004081007A1/fr not_active Ceased
- 2004-02-23 MX MXPA05009660A patent/MXPA05009660A/es active IP Right Grant
- 2004-02-23 UA UAA200508639A patent/UA78437C2/uk unknown
- 2004-02-23 OA OA1200500259A patent/OA13038A/en unknown
- 2004-02-23 AU AU2004220327A patent/AU2004220327B2/en not_active Ceased
- 2004-02-23 HR HR20050798A patent/HRP20050798A2/hr not_active Application Discontinuation
- 2004-02-23 BR BRPI0408248-6A patent/BRPI0408248A/pt not_active IP Right Cessation
- 2004-02-23 KR KR1020077013527A patent/KR20070074667A/ko not_active Withdrawn
- 2004-02-23 RS YUP-2005/0692A patent/RS20050692A/sr unknown
- 2004-03-08 PA PA20048597501A patent/PA8597501A1/es unknown
- 2004-03-09 PE PE2004000256A patent/PE20041057A1/es not_active Application Discontinuation
- 2004-03-10 AR ARP040100770A patent/AR043537A1/es not_active Application Discontinuation
- 2004-03-11 UY UY28225A patent/UY28225A1/es not_active Application Discontinuation
- 2004-03-11 GT GT200400041A patent/GT200400041A/es unknown
- 2004-03-11 TW TW093106481A patent/TW200502234A/zh unknown
- 2004-03-12 US US10/800,328 patent/US7345038B2/en not_active Expired - Fee Related
- 2004-03-12 NL NL1025710A patent/NL1025710C2/nl not_active IP Right Cessation
2005
- 2005-08-10 ZA ZA200506373A patent/ZA200506373B/en unknown
- 2005-08-15 IL IL170290A patent/IL170290A/en not_active IP Right Cessation
- 2005-09-02 NO NO20054095A patent/NO20054095L/no unknown
- 2005-09-12 MA MA28495A patent/MA27747A1/fr unknown
- 2005-09-12 TN TNP2005000224A patent/TNSN05224A1/fr unknown
- 2005-09-12 EC EC2005006011A patent/ECSP056011A/es unknown
2006
- 2006-10-26 JP JP2006291545A patent/JP2007051155A/ja active Pending
2010
- 2010-07-23 AU AU2010203303A patent/AU2010203303A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1608648A1 (fr)	2005-12-28
AU2004220327B2 (en)	2010-06-24
HRP20050798A2 (en)	2006-02-28
ZA200506373B (en)	2006-10-25
CA2518740A1 (fr)	2004-09-23
MA27747A1 (fr)	2006-02-01
NL1025710C2 (nl)	2005-10-10
IL170290A (en)	2011-02-28
OA13038A (en)	2006-11-10
JP3910627B2 (ja)	2007-04-25
HK1085725A1 (zh)	2006-09-01
AU2004220327A1 (en)	2004-09-23
KR100767854B1 (ko)	2007-10-17
UY28225A1 (es)	2004-11-08
JP2006519830A (ja)	2006-08-31
GT200400041A (es)	2005-03-23
AP2005003390A0 (en)	2005-09-30
UA78437C2 (en)	2007-03-15
CN100389115C (zh)	2008-05-21
KR20070074667A (ko)	2007-07-12
AU2010203303A1 (en)	2010-08-12
CN1759116A (zh)	2006-04-12
BRPI0408248A (pt)	2006-03-01
KR20050113221A (ko)	2005-12-01
PA8597501A1 (es)	2005-05-24
TW200502234A (en)	2005-01-16
ECSP056011A (es)	2006-01-27
EA200501148A1 (ru)	2006-04-28
CA2518740C (fr)	2011-01-11
TNSN05224A1 (fr)	2007-06-11
NL1025710A1 (nl)	2004-09-14
PL378749A1 (pl)	2006-05-15
PE20041057A1 (es)	2005-01-22
US7345038B2 (en)	2008-03-18
WO2004081007A1 (fr)	2004-09-23
JP2007051155A (ja)	2007-03-01
US20050026922A1 (en)	2005-02-03
NO20054095D0 (no)	2005-09-02
RS20050692A (sr)	2007-11-15
MXPA05009660A (es)	2005-10-20
AR043537A1 (es)	2005-08-03
EP1608648B1 (fr)	2012-07-18
EA009527B1 (ru)	2008-02-28

Publication	Publication Date	Title
CY1121699T1 (el)	2020-07-31	Ενωσεις τριαζινης ως αναστολεις κινασης ρ13 και mtor
CO5700824A2 (es)	2006-11-30	Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
AR054560A1 (es)	2007-06-27	Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
EA200600892A1 (ru)	2006-12-29	Новые хинолиновые производные
DE602004018617D1 (de)	2009-02-05	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
EA200970379A1 (ru)	2009-08-28	Бициклические гетероароматические соединения
ZA200609261B (en)	2008-08-27	Fused quinoline derivative and use thereof
TW200833675A (en)	2008-08-16	Nicotinamide derivatives
EA200500018A1 (ru)	2005-06-30	Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
TW200718692A (en)	2007-05-16	Dihydrobenzofuran derivatives and uses thereof
MXPA05009660A (es)	2005-10-20	Derivados azabiciclicos de piridiloximetilo y bencisoxazol.
NO20073720L (no)	2007-11-05	Heterocyklisk substituerte fenylmetanoner som inhibitorer av glycintransportorer
DE602004016123D1 (de)	2008-10-09	Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
TW200740805A (en)	2007-11-01	Novel compounds
NO20093275L (no)	2010-02-04	1,3-Dihydroimidazol-2-thione derivater som inhibitorer av dopamin-beta-hydroksylase
DE602006011752D1 (de)	2010-03-04	Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
MXPA05007494A (es)	2005-09-21	Nuevos compuestos.
PE20030761A1 (es)	2003-09-05	Derivados del 7-amino-benzotiazol
CR20230382A (es)	2023-09-06	Derivados de tetrahidroazepina bicíclicos para el tratamiento del cáncer
WO2005003087A3 (fr)	2005-03-17	Composes nouveaux utiles comme agents anti-bacteriens
ATE453389T1 (de)	2010-01-15	Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
EA200501881A1 (ru)	2006-06-30	ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ ПИРРОЛА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ HMG-CoA
NO20051844L (no)	2005-04-15	Piperazinderivater og fremgangsmate for anvendelse derav.
NO20071230L (no)	2007-05-04	Oksazolidinoner inneholdende oksindoler som antibakterielle midler
JOP20240119A1 (ar)	2024-05-23	مشتقات نافثيريدينون لمعالجة مرض أو اضطراب